Persistence of switching to fingolimod compared with other oral and injectable therapies in patients with multiple sclerosis

Trial Profile

Persistence of switching to fingolimod compared with other oral and injectable therapies in patients with multiple sclerosis

Completed
Phase of Trial: Phase IV

Latest Information Update: 08 May 2017

At a glance

  • Drugs Fingolimod (Primary) ; Dimethyl fumarate; Glatiramer acetate; Interferon; Teriflunomide
  • Indications Multiple sclerosis
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 08 May 2017 New trial record
    • 28 Apr 2017 Results presented at the 69th Annual Meeting of the American Academy of Neurology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top